Choose your preferred way to stay informed of new case launches and settlement deadlines
Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. Following this news, shares of AN2 Therapeutics stock over 73% in premarket trading.
In order to be eligible to join the ANTX class action lawsuit, you must have incurred a loss on shares of AN2 Therapeutics purchased during the class period listed above.
TOP
